Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.52
-$0.08-5.00%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.11M | 18.22M | 17.96M | 13.47M | 3.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.11M | 18.22M | 17.96M | 13.47M | 3.75M |
| Cost of Revenue | 8.18M | 3.89M | 8.38M | 9.46M | 2.60M |
| Gross Profit | 1.93M | 14.33M | 9.58M | 4.02M | 1.15M |
| SG&A Expenses | 2.60M | 3.00M | 2.60M | 3.48M | 3.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.26M | 11.01M | 13.97M | 15.90M | 8.60M |
| Operating Income | -4.15M | 7.21M | 3.99M | -2.43M | -4.86M |
| Income Before Tax | -3.73M | 7.32M | 3.84M | -2.27M | -4.73M |
| Income Tax Expenses | -113.00K | 822.00K | 607.00K | -69.00K | -138.00K |
| Earnings from Continuing Operations | -3.62M | 6.49M | 3.24M | -2.20M | -4.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.62M | 6.49M | 3.24M | -2.20M | -4.60M |
| EBIT | -4.15M | 7.21M | 3.99M | -2.43M | -4.86M |
| EBITDA | -3.80M | 7.54M | 4.32M | -2.11M | -4.53M |
| EPS Basic | -0.05 | 0.09 | 0.04 | -0.03 | -0.06 |
| Normalized Basic EPS | -0.03 | 0.07 | 0.03 | -0.02 | -0.04 |
| EPS Diluted | -0.05 | 0.06 | 0.03 | -0.03 | -0.06 |
| Normalized Diluted EPS | -0.03 | 0.04 | 0.03 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 76.61M | 70.22M | 73.55M | 73.31M | 73.04M |
| Average Diluted Shares Outstanding | 76.61M | 104.33M | 81.22M | 73.31M | 73.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |